Loading organizations...
Pfizer R&D Innovate embodies the company’s core strategy for discovering and developing novel biopharmaceutical products. It conducts extensive research across therapeutic areas including Internal Medicine, Inflammation & Immunology, Vaccines, and Oncology. This approach integrates advanced science and diverse modalities to create effective treatments and preventative solutions for global health.
The innovative foundation for Pfizer R&D Innovate originates from Pfizer's 1849 inception. Cousins Charles Pfizer and Charles Erhart founded the company in New York, driven by applying chemical expertise to public health. This early dedication to scientific inquiry and impactful product creation established a lasting legacy.
Patients worldwide benefit from Pfizer R&D Innovate's efforts, accessing life-enhancing medicines and vaccines. Its vision focuses on advancing scientific understanding to deliver transformative therapies that improve and extend human life. This mission redefines healthcare by addressing critical unmet medical needs via scientific progress.
Pfizer R&D Innovate has 1 tracked investment across 1 company. The latest tracked deal is $50.0M Series A in Jnana Therapeutics in December 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2017 | Jnana Therapeutics | $50.0M Series A | — | ARCH Venture Partners, Avalon Ventures, Bison Ventures, Polaris Partners, RA Capital, Samsara BioCapital, SoftBank Investment Advisers, Versant Ventures, AbbVie Ventures, Amir Nashat |
